about
Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.Ceftaroline in complicated skin and skin-structure infections.Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaEfficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolatesIn vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011.Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin.Summary of ceftaroline fosamil clinical trial studies and clinical safety.Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates.Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activityMethicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic modelCeftaroline potency among 9 US Census regions: report from the 2010 AWARE ProgramInterim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species
P921
Q30452801-CFC2B831-8B3D-47D2-A879-48FB4ECBFAD5Q33938055-20B790D4-903D-4656-B135-B5AD670624B8Q35715381-E7C09E44-88FE-40D7-B839-1EF0C938B8A2Q35752997-386A82AD-D438-4F07-9A13-84166F948943Q35941308-966D64E0-65BC-4A0B-8B60-FBF1A16268CDQ36018756-59FC13D4-D7E3-4456-983D-3DE117682D2AQ38006689-41597E47-C8AB-4029-A025-3DE2FC1DB68AQ38024092-4BA3690C-0713-41D9-9694-7718F6ABF206Q38035807-F767BCDD-911F-467D-9AD1-A3F5F6C73FDDQ41182854-F313BE92-79B5-4D60-A798-DAF7257644A5Q41919138-5BBE170C-26FF-4A80-8959-1A85C8DBF247Q41984202-D206D224-7BE0-44A6-894E-DBF0BBE7F067Q41985451-6A27639D-AAA8-4E6C-AD7E-0BBE31C26AA9Q42696736-97771D44-01CB-4112-AF85-2303031AB4EDQ43884247-000360A5-5AA1-4E33-A70A-33C95CD1AF5EQ44814819-6627FC5F-787E-4655-B4AD-4A4476AE754DQ47384814-B906F12A-FEEC-4E02-A612-B81A74F79EAFQ50916931-FCF885A9-4D6E-463D-85F4-C905BD71E472Q50916936-EBA0E2E5-D518-4691-8C92-F9D7DF8880B7Q53657706-9C28AFA3-F15D-437B-A1CF-4325414F9642Q83787585-E81EC591-379B-4DCF-99C3-58E0E3B5089AQ84824124-B4635996-A810-44DF-B303-3B495E7C01CEQ87396807-9D3084B1-EFBC-4A98-BE8B-0DC57FD476FA
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
ceftarolin
@nn
ceftaroline
@en
type
label
ceftarolin
@nn
ceftaroline
@en
altLabel
PPI 0903M
@en
T 91825
@en
T-91825
@en
prefLabel
ceftarolin
@nn
ceftaroline
@en
P661
P662
P683
P117
P1579
P2017
CCO/N=C(/C1=NSC(=N1)N)\C(=O)N[ ...... S4)C5=CC=[N+](C=C5)C)C(=O)[O-]
P2067
P2115
N0000182263
P231
189345-04-8
P233
CCON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-]
P234
1S/C22H20N8O5S4/c1-3-35-27-13( ...... ,33,34)/b27-13-/t14-,19-/m1/s1
P235
RGFBRLNVZCCMSV-BIRGHMBHSA-N
P274
C₂₂H₂₀N₈O₅S₄
P2868
P2892
P3117
DTXSID90172341
P3345
P652
H36Z0FHR8K